Skip to main content
SpringerLink
Log in

Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: To assess the lifetime diabetes health consequences and cost-effectiveness in Spain of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in overweight and obese patients failing to maintain glycaemic control with metformin monotherapy compared with conventional care of metformin in combination with either sulfonylureas or bedtime insulin.

Research design and methods: The Diabetes Decision Analysis of Cost — Type 2 was adapted for clinical practice and healthcare funding in Spain, and was calibrated with Spanish epidemiological, healthcare resource use and cost data, taking the perspective of the Spanish National Health System. The model simulates lifetime treatment histories, complications and consequences of type 2 diabetes, and associated health outcomes and costs for age and sex-matched cohorts of 1000 overweight and obese patients. The primary health outcome measures compared are glycaemic control, time to insulin, incidence and prevalence of coronary heart disease, stroke, clinical nephropathy, ulceration and amputation, and severe visual loss, and incremental life-years and quality-adjusted life-years (QALYs).

Results: Rosiglitazone in combination with metformin produces better glycaemic control than conventional care of metformin in combination with either sulfonylureas or bedtime insulin in most patients, and extends the viability of combination therapy by between 6 and 13 years before requiring insulin. Rosiglitazone patients have a longer life expectancy, gaining between 106 and 175 additional life-years per 1000 patients, experience fewer episodes of coronary disease and clinical nephropathy, and live for longer periods free of complications. The improvements in morbidity and mortality are projected to yield between 134 and 238 additional QALY per 1000 patients over their lifetime. Discounted incremental cost-effectiveness ratios range from €9406 to €23 514 per QALY gained.

Conclusion: The model predicts that rosiglitazone in combination with metformin is a cost-effective intervention for the treatment of both overweight and obese patients with type 2 diabetes when compared with conventional care in Spain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. International Diabetes Federation. Diabetes Atlas 2001. Brussels: International Diabetes Federation; 2001

    Google Scholar 

  2. Vázquez JA, Gaztambide S, Soto-Pedre E. Estudio prospectivo a 10 años sobre la incidencia y factores de riesgo de diabetes mellitus tipo 2. [in Spanish]. Med Clin (Barc) 2000; 115: 534–9

    Google Scholar 

  3. Mata M, Antoñanzas F, Tafalla M, Sanz P. El coste de la diabetes tipo 2 en España, El estudio CODE-2. [in Spanish]. Gac Sanit 2002; 16: 511–20

    PubMed  CAS  Google Scholar 

  4. Oliva J, Lobo F, Molina B, Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care 2004; 27: 2616–21

    Article  PubMed  Google Scholar 

  5. Goday A, Franch Nadal J, Mata M, et al. Criterios y pautas de terapia combinada en la diabetes tipo 2. Documento de consenso de la Sociedad Española de Diabetes y de la Sociedad Española de Medicina Familiar y Comunitaria [in Spanish]. Endocrinología y Nutrición 2001; 48: 82–97

    Google Scholar 

  6. Bagust A, Hopkinson PK, Maier W, et al. An economic model of the long-term health care burden of type 2 diabetes. Diabetologia 2001; 44: 2140–55

    Article  PubMed  CAS  Google Scholar 

  7. Beale S, Bagust A, Shearer A, et al. Cost-effectiveness of rosiglitazone combination for the treatment of type 2 diabetes in the UK. Pharmacoeconomics 2006; 24 (Suppl. 1): 21–34

    PubMed  CAS  Google Scholar 

  8. Shearer A, Bagust A, Liebl A, et al. Cost-effectiveness of rosiglitazone combination for the treatment of type 2 diabetes in Germany. Pharmacoeconomics 2006; 24 (Suppl. 1): 35–48

    PubMed  CAS  Google Scholar 

  9. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997; 20: 725–34

    Article  PubMed  CAS  Google Scholar 

  10. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20: 735–44

    Article  PubMed  CAS  Google Scholar 

  11. Brown JB, Russell A, Chan W, et al. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000; 50 (Suppl. 3): S15–46

    Article  PubMed  Google Scholar 

  12. Palmer AJ, Brandt A, Gozzoli V, et al. Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract 2000; 50 (Suppl. 3): S47–56

    Article  PubMed  Google Scholar 

  13. Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy and ulceration in diabetes. Diabetes Care 1998; 21: 42–8

    Article  PubMed  CAS  Google Scholar 

  14. Carrl F, Aguilar M, Olveira G, et al. Increased hospital expenditures in diabetic patients hospitalized for cardiovascular diseases. J Diabetes Complicat 2003; 17: 331–6

    Article  Google Scholar 

  15. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2004; 7 September (Epub ahead of print)

    Google Scholar 

  16. Anderson KM, Wilson PWF, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356–62

    Article  PubMed  CAS  Google Scholar 

  17. Stevens RJ, Kothari V, Adler AI, et al. on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKDPS 56). Clin Sci 2001; 101: 671–9

    Article  PubMed  CAS  Google Scholar 

  18. Kothari V, Stevens RJ, Adler AI, et al. for the UK Prospective Diabetes Study Group. (UKPDS 60) Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Risk Engine. Stroke 2002; 33: 1776–81

    Article  PubMed  Google Scholar 

  19. Bagust A, Evans M, Beale S, et al. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. Pharmacoeconomics 2006; 24 (Suppl. 1): 5–19

    PubMed  CAS  Google Scholar 

  20. Campbell IW. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes? Drugs 2000; 60: 1017–28

    Article  PubMed  CAS  Google Scholar 

  21. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25–33

    PubMed  CAS  Google Scholar 

  22. De Fronzo RA, Goodman AM. Metformin Multicenter Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 33: 541–9

    Article  Google Scholar 

  23. Nolan JJ, Jones NP, Patwardhan R, et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000; 17: 287–94

    Article  PubMed  CAS  Google Scholar 

  24. Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002; 51: 3479–85

    Article  PubMed  CAS  Google Scholar 

  25. Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003; 52: 283–90

    Article  PubMed  CAS  Google Scholar 

  26. GlaxoSmithKline. Data on file (1); 2003

  27. National Diabetes Data Group. Diabetes in America. National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases. NIH publication no. 95-1468; 1995

  28. Instituto Nacional de Estadística (INE). Avance de resultados de los Censos de Población y Viviendas. 2001. Available from: http://www.ine.es/inebase/cgi/axi?AXIS_PATH=/TEMPUS1/nebase/temas/t20/e243/p01/a2001/l0/&FILE_AXIS=01001.px&CGI_DEFAULT=/inebase/temas/cgi.opt&COMANDO=SELECCION&CGI_URL=/inebase/cgi/ [Accessed 2003 Nov]

  29. Taylor Nelson Sofres Healthcare S.A. (Spain). Diabetes monitor. Barcelona: Taylor Nelson Sofres Healthcare; 2002

    Google Scholar 

  30. Arteagoitia JM, Larrañaga MI, Rodriguez JL, et al. Incidence, prevalence and coronary heart disease risk level in known type 2 diabetes: a sentinel practice network study in the Basque Country, Spain. Diabetologia 2003; 46: 899–909

    Article  PubMed  CAS  Google Scholar 

  31. Esmatjes E, Goicolea I, Cacho De Pablos PL, et al. Work Group of Diabetic Nefropathy Spanish Diabetes Society: nefropathy in the diabetes mellitus type II: prevalence in Spain. Avances en Diabetologia 1997; 13: 29–35

    Google Scholar 

  32. Cabezas-Cerrato J. The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. Diabetologia 1998; 41: 1263–9

    Article  PubMed  CAS  Google Scholar 

  33. Institute Nacional de Estadística (INE). Defunciones según la Causa de Muerte. 2000. Available from: http://www.ine.es/inebase/cgi/axi?AXIS_PATH=/inebase/temas/t15/p417/a2000/l0/&FILE_AXIS=01001.px&CGI_DEFAULT=/inebase/temas/cgi.opt&COMANDO=SELECCON&CGI_URL=/inebase/cgi/%20<http://www.ine.es/inebase/cgi/axi?AXIS_PATH=/inebase/temas/t15/p417/a2000/l0/&FILE_AXIS=01001.px&CGI_DEFAULT=/inebase/temas/cgi.opt&COMANDO=SELECCION&CGI_URL=/inebase/cgi/ [Accessed 2003 Nov]

  34. Instituto Nacional de Estadística (INE). Consumer Price Index. 2003. Available from: http://www.ine.es/inebase/cgi/um?M=%2Ft25%2Fp138&O=inebase&N=&L=1 [Accessed 2003 Nov]

  35. Estimation of the hospital welfare load in a specific assembly of diagnoses related to the diabetes. Barcelona: IASIST Solucient International; 2003

  36. Gisbert R, Brosa M. Sanitary costs database, version 1.4: SOIKOS 1997–2003. Barcelona: Centre of Studies in Economics of Health and Social Policy; 2003

    Google Scholar 

  37. CMBD Insalud. Analysis of the GRDs. Year 2001. Madrid: National Institute of Health; 2002

    Google Scholar 

  38. Rodriguez-Carmona A, Perez Fontan M, et al. The economic cost of dialysis: a comparison between peritoneal dialysis and in-center haemodialysis in a Spanish unit. Adv Periton Dial 1996; 12: 93–6

    CAS  Google Scholar 

  39. Ballesta M, Pérez AA, Valencia I, et al. Estimación de los Costes Económicos Ocasionados por los Pacientes con Diabetes Mellitus Tipo 2 en el Área Sanitaria Cádiz-San Fernando. 2003. Available from: http://www.cica.es/aliens/jaescadiz/Archivos%20pdf/Archivos%20pdf%20ab/015.pdf [Accessed 2003 Nov]

  40. IMS. Estudio de Prescripciones Médicas. Madrid: International Marketing Services Health; 2002

    Google Scholar 

  41. Farmaindustria. The pharmaceutical industry in figures [in Spanish]. Madrid: Farmaindustria; 2002

    Google Scholar 

  42. Rodríguez CB. En busca de un modelo de asistencia a la vejez [in Spanish]. Revista Española de Economía de la Salud 2002; 1: 12–4

    Google Scholar 

  43. Clua Espuny JL, Puig Junoy J, Queralt Tomás MA, et al. Análisis coste-efectividad de la automonitorización de la glucosa sanguínea en diabéticos tipo 2 [in Spanish]. Gac Sanit 2000; 14: 442–8

    PubMed  CAS  Google Scholar 

  44. Hällsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002; 51: 3479–85

    Article  PubMed  Google Scholar 

  45. Virtanen KA, Hällsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003; 52: 283–90

    Article  PubMed  CAS  Google Scholar 

  46. Velasco JA, Cosín J, Maroto JM, et al. Guías de práctica clínica de la Sociedad Española de Cardiología en prevención cardiovascular y rehabilitación cardíaca [in Spanish]. Rev Esp Cardiol 2000; 53: 1095–120

    PubMed  CAS  Google Scholar 

  47. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular prevention in clinical practice. Eur Heart J 2003; 24: 1601–10

    Article  Google Scholar 

  48. Colhoun HM, Betteridge DJ, Durrington PN, et al. and the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96

    Article  PubMed  CAS  Google Scholar 

  49. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16

    Article  Google Scholar 

  50. Dominguez-Gil A, Soto J. Farmacoeconomía e Investigación de Resultados en la Salud: Principios y Práctica. Situación actual y perspectivas futuras en España [in Spanish]. Madrid: Real Academia Nacional de Farmacia; 2002

    Google Scholar 

  51. Pinto Prades JL, Sánchez Martínez FI. Métodos para la evaluación económica de nuevas prestaciones [in Spanish]. Ministerio de Sanidad y Consumo; 2003

  52. Ortún V. 30.000 euros por AVAC. Economía y Salud Boletín informativo n∘ 49 [in Spanish]. Barcelona: Asociación de Economía de la Salud; 2004

    Google Scholar 

  53. Sacristan JA, Oliva J, Del Llano J, et al. What is an efficient health technology in Spain? Gac Sanit 2002; 16: 334–43

    PubMed  CAS  Google Scholar 

  54. Klein R. Hyperglycaemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258–68

    Article  PubMed  CAS  Google Scholar 

  55. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine.. New York: Oxford University Press; 1996

    Google Scholar 

  56. Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health ca‘re programs.. Oxford: Oxford University Press; 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. York Health Economics Consortium, Market Square, University of York, Vanbrugh Way, Heslington, York, YO10 5NH, UK

    Arran T. Shearer & Adrian Bagust

  2. Clinic University Hospital Valencia, Valencia, Spain

    F. Javier Ampudia-Blasco

  3. GlaxoSmithKline, Madrid, Spain

    Belén Martínez-Lage Álvarez, Isabel Pérez Escolano & Gonzalo París

Authors
  1. Arran T. Shearer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrian Bagust
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Javier Ampudia-Blasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Belén Martínez-Lage Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Isabel Pérez Escolano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gonzalo París
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arran T. Shearer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shearer, A.T., Bagust, A., Ampudia-Blasco, F.J. et al. Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain. PharmacoEconomics 24 (Suppl 1), 49–59 (2006). https://doi.org/10.2165/00019053-200624001-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200624001-00005

Keywords

Search

Navigation